News

PipelineReview.com1h
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
WOBURN, MA, USA I April 27, 2025 I Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody ...
PipelineReview.com1h
Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
DARMSTADT, Germany I April 28, 2025 I Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.
PipelineReview.com1h
Nona Biosciences’ Partner Pfizer Presents Preclinical Data on TOP1i-Based ADC Targeting MSLN at AACR Annual Meeting 2025
CAMBRIDGE, MA, USA I April 27, 2025 I Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), ...
PipelineReview.com12d
Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 15, 2025 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and ...
PipelineReview.com8d
Akeso’s Ebdarokimab ( IL – 12/IL – 23 Dual – Targeted Monoclonal Antibody) Approved in China for Moderate – to – Severe Plaque Psoriasis
HONG KONG, China I April 18, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal ...
PipelineReview.com8d
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
PARIS, France and TARRYTOWN, NY, USA I April 18, 2025 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of ...
PipelineReview.com11d
Radiance Announces First Patient Dosing in Phase 1 Clinical Trial of its Next Generation ROR-1 Targeted ADC for Hematologic and Solid Malignancies
BOSTON, MA, USA I April 15, 2025 I Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug ...
PipelineReview.com11d
Sabin Begins Marburg Vaccine Trial in U.S.
WASHINGTON, DC, USA I April 16, 2025 I The Sabin Vaccine Institute has launched a multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine ...
PipelineReview.com11d
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
MELBOURNE, Australia and INDIANAPOLIS, IN, USA I April 16, 2025 I Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces ...
PipelineReview.com12d
Evommune Initiates Phase 2b Trial of MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Chronic Spontaneous Urticaria
PALO ALTO, CA, USA I April 15, 2025 I Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated ...
PipelineReview.com11d
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
GENEVA, Switzerland I April 17, 2025 I Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of ...
PipelineReview.com12d
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
SAN DIEGO, CA, USA I April 15, 2025 I Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new ...